Search

#ClinicalTrials
R
Reuters @reuters.com · London 🇬🇧 · 2d

An experimental drug, daraxonrasib, developed by Revolution Medicines, has shown promise in nearly doubling survival time for patients with advanced pancreatic cancer during clinical trials, despite a high rate of mostly manageable side effects, according to a recently reported study. #PancreaticCancer #ClinicalTrials #CancerResearch #US #IN

www.reuters.com
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
May 6 (Reuters) - An experimental drug from Revolution Medicines (RVMD. O), opens new tab that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side effects, researchers reported on Wednesday.
The New York Times @nytimes.com · New York City 🇺🇸 · 2d

Pam Belluck's article details Amanda Sifford's experience with a new A.L.S. therapy called tofersen, which has shown promising results in improving her lung function and overall health despite the challenges of a severe neurological condition that has afflicted her family. #ALS #Neurology #ClinicalTrials #US #CA

www.nytimes.com
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
Pam Belluck spent time with an A. L. S. patient who is being treated with the new therapy in Miami. Time was running out for Amanda Sifford, she and her doctors could tell.
The Guardian @theguardian.com · London 🇬🇧 · 3d

Organizace Alzheimer's Research UK upozorňuje, že pacienti s Alzheimerovou chorobou přicházejí o možnost účasti v klinických studiích kvůli zpožděným nebo nepřesným diagnózám, což může mít za následek, že nebudou mít přístup k novým léčebným možnostem, v době, kdy počet zkoušených léků na tuto nemoc roste. #AlzheimersResearch #ClinicalTrials #DiagnosisChallenges

www.theguardian.com
Slow Alzheimer's diagnoses 'mean UK patients missing out on experimental treatments'
Alzheimer's Research UK says patients at risk of being left behind as lack of formal or accurate diagnoses closes door to trials People with Alzheimer's disease are missing out on experimental treatments because they are not diagnosed early or accurately enough to be enrolled in clinical trials, a UK charity has said.